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Introduction
Somatic structural variations in the genome - referred to 
by cytogeneticists as translocations, inversions, duplica-
tions and insertions - can be powerful events in tumor 
evolution because they can create fusion genes. Fusion 
genes are formed when part of one gene is juxtaposed to 
another by a structural rearrangement, creating a hybrid 
transcript, or sometimes simply inserting a novel promo-
ter  upstream  of  a  gene.  These  can  be  very  powerful 
oncogenic mutations, not only increasing expression of a 
protein but also changing its activity, subcellular localiza-
tion  or  binding  specificity  [1,2].  Such  fusion  genes  are 
also  clinically  important,  because  some  can  predict 
outcome and determine management, and some may be 
targets for therapy [1]. For example, the BCR-ABL fusion 
gene defines a group of leukemias and is the target of 
treatment with the kinase inhibitor Glivec.
In  stark  contrast  to  leukemias,  lymphomas  and 
sarcomas,  in  which  many  important  oncogenes  have 
been identified at translocation breaks, we have a poor 
understanding of how structural variations contribute to 
carcinogenesis  in  common  epithelial  tumors  [1,2]. 
Although  we  have  relatively  good  knowledge  of  which 
genes can be point-mutated, amplified or deleted in these 
cancers,  the  sheer  number  and  complexity  of  their 
genome rearrangements has made it difficult to identify 
genes at chromosome breakpoints [2]. We have known 
for several years that recurrent gene fusions are found in 
common  epithelial  cancers,  following  the  discovery  of 
the TMPRSS2-ERG and related fusions in prostate cancer 
[3] and EML4-ALK in lung cancer [4]. However, these 
fusions were discovered by essentially one-off methods 
and  it  remains  to  be  seen  whether  these  are  isolated 
examples or the tip of an iceberg.
Stephens  et  al.  [5]  recently  presented  the  first  large-
scale survey of somatically acquired structural variation 
in  the  genomes  of  cancers,  with  the  explicit  goal  of 
discovering  genes  disrupted  and  fused  at  chromosome 
breakpoints.  The  authors  [5]  used  massively  parallel 
paired end sequencing to find genome rearrangements in 
24 breast cancers - 9 of which were from immortal cell 
lines and 15 from primary tumors. Although these data 
pertain to breast cancer, we think many of the findings 
will  also  be  relevant  to  other  common  cancers,  and 
certainly they are consistent with a preceding pilot study 
of two lung cancer cell lines [6]. The Stephens et al. [5] 
study  revealed  that  structural  variants  contribute 
significantly  to  the  mutational  burden  of  many  breast 
cancers, but also that genes are often fused or otherwise 
disrupted by mechanisms we have, so far, not appreciated.
Massively parallel paired end sequencing
Massively parallel sequencing techniques generate very 
large  numbers  of  sequence  reads,  but  the  reads  are 
generally  much  shorter  than  in  traditional  sequencing, 
typically  only  tens  of  base  pairs.  To  use  these  short 
sequence  ‘tags’  efficiently  to  find  structural  rearrange-
ments, ‘paired end read’ strategies have been developed 
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strategies; Figure 1) [6]. The genome is broken into DNA 
fragments  of  selected  size,  for  example  500  base  pairs 
(bp) [5], and a short sequence, for example 37 bp, is read 
from  each  end  of  each  DNA  fragment  to  give  paired 
sequences. Most of the fragments are normal, and their 
paired  reads  map  back  to  the  reference  genome  about 
500 bp apart and in the correct orientation. Structural 
variants  are  discovered  when  read-pairs  map 
unexpectedly, for example to two different chromosomes 
(translocation), too far apart (deletion), or in the wrong 
orientation (tandem duplication or inversion) (Figure 1). 
Considerable  bioinformatic  processing  is  required  to 
interpret the huge volume of sequence data, but millions 
of  paired  reads  are  pruned  down  to  a  hundred  or  so 
structural  variants  per  tumor,  most  of  which  can  be 
confirmed by PCR.
Stephens  et  al.  [5]  estimate  that  50%  of  structural 
variations were detected in their study. This may seem 
like  a  low  figure  but,  as  the  authors  showed,  it  was 
sufficient to identify hundreds of structural variants and 
tens  of  fusion  genes.  The  main  reason  for  missing 
structural  variants  was  that  the  amount  of  sequencing 
was  not  enough  to  sample  all  rearrangements.  Also, 
breakpoints  flanked  by  repeats  may  have  been  missed 
because  reads  from  repetitive  regions  are  currently 
discarded.  We  expect  the  proportion  of  structural 
variants  detected  to  increase  in  the  future  as  more 
sequencing  reads  are  generated,  the  reads  used  are 
longer, and bioinformatic analysis is refined.
Rearrangements in breast cancers are more 
numerous than expected
There were many more structural variants than most in 
the field would have anticipated [5]. For cell lines, the 
median number of rearrangements per sample was 101 
and ranged from 58 to 245. For the tumors, the median 
was 38 and ranged from 1 to 231. Approximately 85% 
were intrachromosomal and less than 2 Mb [5], which 
explains why earlier molecular cytogenetic approaches, 
such as spectral karyotyping, array comparative genomic 
hybridization  (CGH)  and  array  painting  [7],  under  esti-
mated the number of rearrangements. These aberrations 
would not have been visible in metaphase chromosomes 
and many were copy-number neutral or too small to have 
shown up in most array CGH experiments.
Many fusion genes were predicted and several 
were expressed
Many of the structural changes that Stephens et al. [5] 
found juxtaposed the coding regions of two genes. An 
important observation, extending earlier studies [2,7,8], 
was that some breast cancers can express several fused 
genes. Stephens et al. [5] showed that 21 novel fusion 
genes  were  expressed  and  in  frame  so  potentially 
produced a functional fusion protein. Allowing for the 
estimated 50% detection rate, this would equate to two 
functional fusion genes per case. Most of the fusion genes 
were of unknown function but several involved known or 
likely  cancer  genes,  such  as  ETV6,  which  is  a  known 
target  of  translocations  and  encodes  a  member  of  the 
oncogenic  Ets  transcription  factor  family,  and  EHF, 
which also encodes an Ets family member. Some genes 
seemed to be rearranged in several of the 24 samples but 
no recurrent gene fusions were identified by fluorescence 
in situ hybridization (FISH) or RT-PCR in a larger second 
set of tumors [5]. This may simply be a reflection of the 
heterogeneity of breast cancer - the samples used were 
chosen to represent a range of different tumor subtypes - 
or it may be that aberrant expression of an important 3’ 
gene can be driven by several different 5’ fusion transcript 
partners, as happens, for example, to the Ets-related gene 
ERG in prostate cancers.
Figure 1. Mapping structural variants using the paired end read 
strategy. (a) A region of genome containing a translocation junction 
between two different chromosomes (red and blue). (b) The entire 
genome is fragmented, and fragments of a desired size, typically 
500 bp, are selected. (c) The ends of the fragments are sequenced 
for a small fraction of the fragment length, typically 35 bp (black 
arrows). The Stephens et al. [5] study used 500 bp fragments and 
37 bp sequencing reads but other combinations are possible. For 
variations, see [2]. (d) The paired sequence tags are mapped back to 
the reference genome. Most pairs map back about 500 bp from each 
other on the same chromosome, but (e) the read pair spanning the 
translocation breakpoint maps back to two different chromosomes in 
the reference genome.
(a) A region with a translocation junction
(b) The whole genome is fragmented and fragments of 
     a given size selected
(c) Sequence is generated from the ends of each fragment
(d) Read pairs are aligned to the reference genome
(e) Most pairs map normally but structural variants map 
      unexpectedly
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An  unexpected  finding  [5]  was  a  number  of  somatically 
acquired tandem duplications, a kind of structural change 
that has rarely been detected until recently but is interesting 
because it can lead to gene fusion [9]. A tandem duplication 
occurs when a small region from 3 kb to greater than 1 Mb 
is  duplicated,  usually  in  a  head-to-tail  orientation.  Some 
tumors  showed  a  distinctly  higher  number  of  tandem 
duplications than the others, which led the authors [5] to 
suggest that they were generated by a specific repair defect. 
The BRCA1 and BRCA2 mutant tumors had fewer tandem 
duplications than average, so the aberrant mechanism was 
probably not related to these pathways.
The second surprising finding [5] was that many small 
tandem  duplications,  inversions  and  deletions  were 
entirely within genes. In many cases this affected the exon 
structure at the transcript level and novel isoforms were 
observed. Some of these rearrangements were in putative 
oncogenes, such as the transcription-factor-encoding gene 
RUNX1, so it is plausible that oncogenic activation could 
have  occurred  by  removing  or  reshuffling  exons  that 
encode  a  repressive  protein  domain.  Well-characterized 
tumor suppressor genes such as the retinoblastoma gene 
RB  also  had  internal  rearrangements  and  it  is  possible 
these genes were inactivated through frame shift in the 
transcript or by removing important protein domains.
Two questions arise from these observations [5]: firstly, 
whether the roles of genes such as RUNX1 and RB have 
been  underestimated  in  breast  cancer,  because  these 
kinds  of  mutation  would  not  be  detected  by  Sanger 
sequencing  studies  on  individual  coding  exons;  and 
secondly, whether there are numerous small rearrange-
ments of this kind in other, karyotypically normal, cancers.
Drivers and passengers?
It is remarkable how many mutations, whether sequence-
level, epigenetic or structural, are now being discovered in 
cancer  genomes  [5,10,11].  Many  are  probably  ‘passenger’ 
mutations, that is, random mutational noise, but some must 
be selected, ‘driver’ events and, as the number and variety of 
known mutations increases, estimates for the number of 
‘driving’ mutations in cancer are tending to increase [2,12].
The  problem  of  distinguishing  driver  and  passenger 
mutations is as acute for structural mutations as it is for 
point mutations [10-13]. Stephens et al. [5] estimate that 
approximately 2% of genome rearrangements of the types 
they found would generate an in-frame fusion gene by 
chance.  They  observed  1.6%,  which  suggests  that  the 
majority  of  gene  fusions,  like  the  majority  of  point 
mutations, are not selected events.
Conclusions
The Stephens et al. [5] study is the first indication that 
genome-wide  structural  analysis  of  a  relatively  large 
number of samples, including primary tumors, is already 
an achievable goal. More importantly, it illustrates that 
such studies are worthwhile as they can create a large 
yield of new candidate oncogenes and tumor suppressor 
genes.
Clearly, the next step is to find genes or gene families 
that are recurrently fused or rearranged in a subset of 
tumors. Thanks to the methodologies and bioinformatic 
tools already validated by pilot studies [5,6] we can expect 
large surveys of several cancer types to appear within 2 or 
3  years.  This  will  allow  us  to  address  the  question  of 
recurrence and move on to establish the clinical relevance 
and potential for targeted intervention.
For  the  time  being,  massively  parallel  paired  end 
sequencing will remain a research tool, but the basic cost 
of an analysis like that of Stephens et al. [5] is already 
down  to  a  few  thousands  of  euros  per  case,  so  it  is 
conceivable that we will see it used in the clinic in the not 
too distant future. Indeed, while this article was in press, 
Velculescu  and  colleagues  [14]  announced  a  possible 
clinical  application,  using  paired  end  reads  to  find  a 
structural ‘fingerprint’ of a tumor that could be detected 
in  the  patient’s  serum  and  so  used  to  monitor 
progression.
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